What happened
The FDA approved a supplemental application for Mounjaro (tirzepatide) in the United States. The new indication covers reducing major cardiovascular event risk in adults with type 2 diabetes who are at high cardiovascular risk.
What we know
The regulatory letter identifies SURPASS-CVOT, which compared tirzepatide with dulaglutide, as the supporting trial. It also updates warnings concerning diabetic retinopathy complications.
What it does not mean
A US decision does not itself change European indications and is not an individual treatment recommendation. Mounjaro's diabetes indication should also not be conflated with weight-management authorisations for tirzepatide in other markets.
Why it matters
This is a specific regulatory extension within type 2 diabetes care. The official label and relevant jurisdiction remain essential when interpreting who the medicine is authorised for.